Zhimeng Biopharma Wins Approval to Launch Phase 2 Epilepsy Trial
Shanghai, China – September 11, 2025 – Shanghai Zhimeng Biopharma, Inc. today announced that its investigational therapy CB03-154, a...
CB03-154
Advertisement
Advertisement
Advertisement
Shanghai, China – September 11, 2025 – Shanghai Zhimeng Biopharma, Inc. today announced that its investigational therapy CB03-154, a...
Advertisement